Publicaciones en colaboración con investigadores/as de University of Western Ontario (2)

2019

  1. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    Cardiovascular Diabetology, Vol. 18, Núm. 1

2018

  1. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

    Diabetes, Obesity and Metabolism, Vol. 20, Núm. 1, pp. 200-205